• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

泛素特异性蛋白酶14(USP14)在多发性骨髓瘤细胞的细胞黏附介导的耐药性(CAM-DR)中的作用。

The role of ubiquitin-specific protease 14 (USP14) in cell adhesion-mediated drug resistance (CAM-DR) of multiple myeloma cells.

作者信息

Xu Xiaohong, Liu Jing, Shen Chaoyan, Ding Linlin, Zhong Fei, Ouyang Yu, Wang Yuchan, He Song

机构信息

Department of Pathology, Affiliated Cancer Hospital of Nantong University, Nantong, Jiangsu Province, China.

Jiangsu Province Key Laboratory for Inflammation and Molecular Drug Target, Nantong University, Nantong, Jiangsu Province, China.

出版信息

Eur J Haematol. 2017 Jan;98(1):4-12. doi: 10.1111/ejh.12729. Epub 2016 Nov 2.

DOI:10.1111/ejh.12729
PMID:26710889
Abstract

OBJECTIVE

Cell adhesion-mediated drug resistance (CAM-DR) is one of the mechanisms underlying the drug resistance in multiple myeloma (MM). Ubiquitin-specific protease 14 (USP14) is downregulated in the apoptotic model and upregulated in the adhesive model of MM. This study was undertaken to determine the role of USP14 in CAM-DR of MM cells.

METHODS

We examined the expression of USP14 in the apoptotic model of MM. The mechanism of USP14 in the process of apoptosis was further explored by flow cytometry assay and co-immunoprecipitation. We then performed the cell co-culture and adhesion assay and cell viability assay to investigate the effect of USP14 on adhesive rate and drug resistance in MM.

RESULTS

We discovered that USP14 played a negative role in cell apoptosis, which is correlated with Bcl-xl. Moreover, overexpression of USP14 in MM cell adhesion model could enhance the ability of cell adhesion by regulating Wnt-signaling pathways, thereby promoting the CAM-DR in MM.

CONCLUSION

USP14 participates in CAM-DR of MM through acting as a bridge between Bcl-xl apoptotic pathway and Wnt-signaling pathways and may be represented as a good candidate for pursuing clinical trials in MM.

摘要

目的

细胞黏附介导的耐药性(CAM-DR)是多发性骨髓瘤(MM)耐药的机制之一。泛素特异性蛋白酶14(USP14)在MM的凋亡模型中表达下调,而在黏附模型中表达上调。本研究旨在确定USP14在MM细胞CAM-DR中的作用。

方法

我们检测了MM凋亡模型中USP14的表达。通过流式细胞术检测和免疫共沉淀进一步探究USP14在凋亡过程中的机制。然后进行细胞共培养、黏附实验和细胞活力实验,以研究USP14对MM细胞黏附率和耐药性的影响。

结果

我们发现USP14在细胞凋亡中起负性作用,这与Bcl-xl相关。此外,在MM细胞黏附模型中过表达USP14可通过调节Wnt信号通路增强细胞黏附能力,从而促进MM中的CAM-DR。

结论

USP14通过作为Bcl-xl凋亡通路和Wnt信号通路之间的桥梁参与MM的CAM-DR,可能是MM临床试验的良好候选靶点。

相似文献

1
The role of ubiquitin-specific protease 14 (USP14) in cell adhesion-mediated drug resistance (CAM-DR) of multiple myeloma cells.泛素特异性蛋白酶14(USP14)在多发性骨髓瘤细胞的细胞黏附介导的耐药性(CAM-DR)中的作用。
Eur J Haematol. 2017 Jan;98(1):4-12. doi: 10.1111/ejh.12729. Epub 2016 Nov 2.
2
Cell adhesion mediated drug resistance (CAM-DR): role of integrins and resistance to apoptosis in human myeloma cell lines.细胞黏附介导的耐药性(CAM-DR):整合素的作用及人骨髓瘤细胞系对凋亡的抗性
Blood. 1999 Mar 1;93(5):1658-67.
3
Elucidating the expression and function of Numbl during cell adhesion-mediated drug resistance (CAM-DR) in multiple myeloma (MM).阐明 Numbl 在多发性骨髓瘤(MM)细胞黏附介导的药物耐药性(CAM-DR)中的表达和功能。
BMC Cancer. 2019 Dec 30;19(1):1269. doi: 10.1186/s12885-019-6446-y.
4
Expression of vaccinia-related kinase 1 (VRK1) accelerates cell proliferation but overcomes cell adhesion mediated drug resistance (CAM-DR) in multiple myeloma.牛痘相关激酶1(VRK1)的表达可加速细胞增殖,但能克服多发性骨髓瘤中细胞黏附介导的耐药性(CAM-DR)。
Hematology. 2016 Dec;21(10):603-612. doi: 10.1080/10245332.2016.1147678. Epub 2016 Jun 18.
5
Upregulation of ADAM12 contributes to accelerated cell proliferation and cell adhesion-mediated drug resistance (CAM-DR) in Non-Hodgkin's Lymphoma.ADAM12的上调促成非霍奇金淋巴瘤中细胞增殖加速及细胞黏附介导的耐药性(CAM-DR)。
Hematology. 2017 Oct;22(9):527-535. doi: 10.1080/10245332.2017.1312205. Epub 2017 Apr 10.
6
Cell adhesion downregulates the expression of Homer1b/c and contributes to drug resistance in multiple myeloma cells.
Oncol Rep. 2016 Mar;35(3):1875-83. doi: 10.3892/or.2015.4532. Epub 2015 Dec 29.
7
Wnt3/RhoA/ROCK signaling pathway is involved in adhesion-mediated drug resistance of multiple myeloma in an autocrine mechanism.Wnt3/RhoA/ROCK信号通路以自分泌机制参与多发性骨髓瘤的黏附介导耐药。
Mol Cancer Ther. 2007 Jun;6(6):1774-84. doi: 10.1158/1535-7163.MCT-06-0684.
8
Inhibition of ubiquitin‑specific protease 14 promotes connexin 32 internalization and counteracts cisplatin cytotoxicity in human ovarian cancer cells.抑制泛素特异性蛋白酶 14 可促进连接蛋白 32 内化并拮抗顺铂对人卵巢癌细胞的细胞毒性。
Oncol Rep. 2019 Sep;42(3):1237-1247. doi: 10.3892/or.2019.7232. Epub 2019 Jul 15.
9
ADP-ribosylation factor 1 (ARF1) takes part in cell proliferation and cell adhesion-mediated drug resistance (CAM-DR).ADP核糖基化因子1(ARF1)参与细胞增殖和细胞黏附介导的耐药性(CAM-DR)。
Ann Hematol. 2017 May;96(5):847-858. doi: 10.1007/s00277-017-2949-2. Epub 2017 Feb 25.
10
Bortezomib overcomes cell-adhesion-mediated drug resistance through downregulation of VLA-4 expression in multiple myeloma.硼替佐米通过下调多发性骨髓瘤中VLA-4的表达克服细胞黏附介导的耐药性。
Oncogene. 2009 Jan 15;28(2):231-42. doi: 10.1038/onc.2008.385. Epub 2008 Oct 13.

引用本文的文献

1
Drug resistance mechanisms and treatment strategies mediated by Ubiquitin-Specific Proteases (USPs) in cancers: new directions and therapeutic options.泛素特异性蛋白酶(USPs)介导的癌症耐药机制及治疗策略:新方向和治疗选择。
Mol Cancer. 2024 May 3;23(1):88. doi: 10.1186/s12943-024-02005-y.
2
USP14 promotes the malignant progression and ibrutinib resistance of mantle cell lymphoma by stabilizing XPO1.USP14 通过稳定 XPO1 促进套细胞淋巴瘤的恶性进展和伊布替尼耐药性。
Int J Med Sci. 2023 Apr 1;20(5):616-626. doi: 10.7150/ijms.80467. eCollection 2023.
3
Targeted therapy for cisplatin-resistant lung cancer via aptamer-guided nano-zinc carriers containing USP14 siRNA.
通过适配体引导的含USP14 siRNA的纳米锌载体对顺铂耐药肺癌进行靶向治疗。
MedComm (2020). 2023 Apr 6;4(2):e237. doi: 10.1002/mco2.237. eCollection 2023 Apr.
4
Bone Marrow Stroma-Induced Transcriptome and Regulome Signatures of Multiple Myeloma.骨髓基质诱导的多发性骨髓瘤转录组和调控组特征
Cancers (Basel). 2022 Feb 13;14(4):927. doi: 10.3390/cancers14040927.
5
Multiple Myeloma: Challenges Encountered and Future Options for Better Treatment.多发性骨髓瘤:面临的挑战和更好治疗的未来选择。
Int J Mol Sci. 2022 Jan 31;23(3):1649. doi: 10.3390/ijms23031649.
6
USP14: Structure, Function, and Target Inhibition.USP14:结构、功能及靶点抑制
Front Pharmacol. 2022 Jan 5;12:801328. doi: 10.3389/fphar.2021.801328. eCollection 2021.
7
Deubiquitinases in hematological malignancies.血液系统恶性肿瘤中的去泛素化酶
Biomark Res. 2021 Aug 28;9(1):66. doi: 10.1186/s40364-021-00320-w.
8
Deubiquitinating Enzymes Orchestrate the Cancer Stem Cell-Immunosuppressive Niche Dialogue: New Perspectives and Therapeutic Potential.去泛素化酶协调癌症干细胞-免疫抑制微环境对话:新视角与治疗潜力
Front Cell Dev Biol. 2021 Jun 9;9:680100. doi: 10.3389/fcell.2021.680100. eCollection 2021.
9
Targeting SIRT1 to inhibit the proliferation of multiple myeloma cells.靶向沉默调节蛋白1以抑制多发性骨髓瘤细胞的增殖。
Oncol Lett. 2021 Apr;21(4):306. doi: 10.3892/ol.2021.12567. Epub 2021 Feb 21.
10
Knockdown of ubiquitin‑specific protease 51 attenuates cisplatin resistance in lung cancer through ubiquitination of zinc‑finger E‑box binding homeobox 1.泛素特异性蛋白酶 51 的敲低通过锌指 E 盒结合同源盒 1 的泛素化来减弱肺癌中的顺铂耐药性。
Mol Med Rep. 2020 Aug;22(2):1382-1390. doi: 10.3892/mmr.2020.11188. Epub 2020 May 27.